Proud For Profits
  • Investing
  • Stock
  • Latest News
  • Economy
  • Investing
  • Stock
  • Latest News
  • Economy
No Result
View All Result
Proud For Profits
No Result
View All Result
Home Stock

Morningstar DBRS outlook for U.S. auto finance in 2025

by
January 8, 2025
in Stock
0
Morningstar DBRS outlook for U.S. auto finance in 2025

Investing.com –Morningstar DBRS expects a stable credit rating environment for the U.S. auto finance sector in 2025, supported by a resilient consumer and steady vehicle sales.

While challenges such as potential tariffs and slower electric vehicle adoption loom for automakers, healthy consumer demand is likely to sustain new auto loan originations. Affordability pressures on new vehicles could also drive robust used vehicle financing and keep used car values strong.

Large auto finance firms are expected to post solid earnings, but smaller players focused on nonprime borrowers may face headwinds from elevated provisioning and higher funding costs amid persistent interest rate pressures.

Morningstar anticipates a softening in credit performance as the cycle matures, particularly among nonprime borrowers, as strained household budgets grapple with high living costs. However, funding access for sector companies remained robust in 2024 and is expected to continue.

Potential tariffs on new vehicle imports could pressure the economy but may boost demand for used cars, benefiting used vehicle lenders and mitigating loss severities by keeping used vehicle prices firm, the note added.

“We expect earnings for the large auto finance companies to be resilient in 2025, benefiting from solid levels of originations, partially offset by elevated funding expense and higher credit costs,” analyst wrote.   

This post appeared first on investing.com
Previous Post

Berkshire shareholder seeks committee to oversee AI at Buffett’s company

Next Post

Sana Biotech’s islet cell therapy shows promise in diabetes; shares surge 150% postmarket

Next Post
Sana Biotech’s islet cell therapy shows promise in diabetes; shares surge 150% postmarket

Sana Biotech’s islet cell therapy shows promise in diabetes; shares surge 150% postmarket

Enter Your Information Below To Receive Trading Ideas and Latest News

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    Popular News

    Nearly all of DC shut down for Trump’s inauguration. So why was there no designated survivor?

    Nearly all of DC shut down for Trump’s inauguration. So why was there no designated survivor?

    January 22, 2025
    Trump’s FBI overhaul begins as Acting Director Brian Driscoll puts ‘untouchable’ feds on notice: former agent

    Trump’s FBI overhaul begins as Acting Director Brian Driscoll puts ‘untouchable’ feds on notice: former agent

    January 22, 2025
    5 Top Canadian Oil and Gas Dividend Stocks in 2025

    5 Top Canadian Oil and Gas Dividend Stocks in 2025

    January 22, 2025
    Track all markets on TradingView

    About Proud For Profits

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Main Categories

    • Investing
    • Stock
    • Latest News
    • Economy

    Latest News

    • Nearly all of DC shut down for Trump’s inauguration. So why was there no designated survivor?
    • Trump’s FBI overhaul begins as Acting Director Brian Driscoll puts ‘untouchable’ feds on notice: former agent
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 proudforprofits.com | All Rights Reserved

    No Result
    View All Result
    • Investing
    • Stock
    • Latest News
    • Economy

    Copyright © 2025 proudforprofits.com | All Rights Reserved